To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the cookie policy

Get updates

When you see
uveal melanoma,

Uveal melanoma (UM) is a rare tumor of the eye1,2

UM is the most common primary intraocular malignancy3

While UM can arise from melanocytes anywhere in the uveal tract, it most commonly occurs in the choroid.2

Occurrence by site2

Eye illustration Eye illustration

Other, less common primary intraocular malignancies include vitreoretinal lymphoma and retinoblastoma.4

ink drop sequence
UM accounts for only
of all melanomas.1,3
people per year diagnosed
with UM globally5
diagnosed in the US6,7
diagnosed in the EU278

EU27, the 27 countries constituting the European Union.

Think uveal melanoma brochure

Think uveal melanoma brochure

Please download the brochure for more information on uveal melanoma.


Would you recognize a patient at risk?

patient image Silhouette
Risk factors that predispose patients to developing UM include:
  • Caucasian2
  • light-colored irides9
  • median age: 62 years, with peak incidence at 55 years2,10,11,a
  • BAP1 mutation12
a Patients carrying the BAP1 mutation typically present at a younger age, between 30 and 59 years of age.10 BAP1BRCA1-associated protein 1; BRCA1, breast cancer 1.

Additional risk factors may include:

Preexisting medical conditions such as congenital ocular melanocytosis, melanocytoma, neurofibromatosis, and ocular nevi (benign melanocytic lesions that can rarely develop into melanomas).2,9,13

“I was fitted for the contacts, and afterward, during the eye exam, the ophthalmologist said, ‘There’s a shadow in the back of your left eye. May I dilate your eye?’ He came back and said, ‘I’ve scheduled an appointment for you to see a specialist . . . I was hoping I wouldn’t need to tell you this, but this may be a matter of life and death. I’m very serious—you need to keep this eye appointment.’”—Patient with UM

Symptoms of UM

illustration of eye

UM can be asymptomatic or present with a variety of symptoms, making annual dilated eye exams ideal.3

Click below to see how patients may experience symptoms of UM. If your patients are experiencing these symptoms, a closer investigation may be warranted.

The vast majority of cases, more than 90%, show no signs of systemic disease at diagnosis.15

Given that patient survival correlates with tumor size and staging, early and accurate diagnosis is particularly important for patient outcomes.13,16-18

Detecting UM

Detecting UM

Watch Bertil Damato, MD, PhD, discuss the importance of systematic examinations.

Play video

Detection and diagnosis of UM can be challenging depending on the size, location, and appearance of the lesion2

Location of UM by type

Eye depicting tumors Eye depicting tumors
Different tumors

Different tumors

Watch Bertil Damato, MD, PhD, discuss diagnosis and timely referral.

Play video

In addition to growth of lesions, ophthalmologists pay especially close attention to other attributes when distinguishing small melanomas from benign lesions, including19:

  • thickness
  • subretinal fluid
  • orange pigment
  • tumor margin
  • ultrasound hollowness
  • absence of a halo of lighter pigmentation around the growth

Patient treatment and prognosis

Surgery and radiation are the primary treatment options for UM10,20

Enucleation (removal of the eye) does not seem to improve survival compared with brachytherapy (focal delivery of radiation to the tumor). Therefore, treatment for primary disease has focused on vision- and eye-preserving techniques.10

  • Radiation iconMost primary UM tumors are treated with plaque brachytherapy.10
  • Surgery iconSurgical approaches include transretinal endoresection and transscleral exoresection (which can still lead to partial sight loss or blindness).10,21
  • Doctor iconOther therapies include proton beam radiotherapy, stereotactic radiotherapy, transpupillary thermotherapy, and photodynamic therapy.10,21
  • Missing eye iconEnucleation is performed in approximately 20% of cases.22
ink drop sequence
Although local control of tumors is associated with impressive response rates,
up to 50%
of patients will go on to develop metastatic UM (mUM).1,10

Sites of metastasis

UM cells spread hematogenously, most commonly metastasizing to the liver and becoming a systemic disease that can also involve the lungs, skin, and bones.5,23

Lungs Liver Skin Bones

Studies have indicated that the risk for metastasis varies and is influenced by clinical characteristics of both the patient and the tumor, including24,25:

  • somatic mutations in the tumor
  • histopathological features
  • tumor diameter and thickness
  • ciliary body involvement
  • advanced age
  • male gender

Need more information?

We’ve gathered some resources to help you assist patients and caregivers.


Get the latest updates in your inbox

Sign up to receive e-mail updates about new content on this website, including information about UM, expert clinical perspectives, and patient resources.

  • Ocular oncologist
  • Ophthalmologist
  • Optometrist
  • Retina specialist
  • Dermatologic oncologist
  • Medical oncologist
  • Other healthcare professional


You have requested to no longer receive e-mail communications from ThinkUvealMelanoma.com.

Please verify your e-mail address below to confirm.

  1. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38-44. doi:10.1136/bjophthalmol-201‌6-30‌9034
  2. Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279-289. doi:10.2147/OPTH.S89591
  3. Mahendraraj K, Lau CSM, Lee I, Chamberlain RS. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973–2012). Clin Ophthalmol. Published online October 25, 2016. 2016;10:2‌113-21‌19. doi:10.2147/OPTH.S1‌13623
  4. Nagarkatti-Gude N, Wang Y, Ali MJ, Honavar SG, Jager MJ, Chan CC. Genetics of primary intraocular tumors. Ocul Immunol Inflamm. Published online September 7, 2012. 2012;201(4):244-254. doi:10.3109/09273948.2012.702843
  5. Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743. doi:10.1101/gad.296962.117
  6. Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013;6(7):123‌0-124‌4. Accessed April 14, 2020. http://www.ijcep.com/files/ijcep1304033.pdf
  7. About ocular melanoma. Ocular Melanoma Foundation. Accessed April 14, 2020. http://ww‌w.ocularmelanoma.o‌rg/about-om.h‌tm
  8. Non skin melanoma—malignant melanoma of uvea—tabular results. Search results. RARECARE: Surveillance of Rare Cancers in Europe. Accessed April 14, 2020. http://dcnapp4.dcn.ed.ac.uk/rcnet/searchpage.aspx
  9. Nathan P, Cohen V, Coupland S, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2‌404-241‌2. doi:10.1016/j.ejca.2015.07.013
  10. Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:175883‌4018757‌175. doi:10.1177/1758‌8340187‌57175
  11. Virgili G, Gatta G, Ciccolallo L, et al; EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):23‌09-23‌15, 2315.e1-23‌15.e2. doi:10.1016/j.ophtha.2007.01.032
  12. Barker CA, Salama AK. New NCCN Guidelines for uveal melanoma and treatment of recurrent or progressive distant metastatic melanoma. J Natl Compr Canc Netw. 2018;16(5.5):646-650. doi:10.6004/jnccn.2018.0042
  13. Weis E, Salopek TG, McKinnon JG, et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol. 2016;23(1):e57-e64. doi:10.374‌7/co‌.23.2859
  14. Rishi PR, Shields CL, Khan MA, Patrick K, Shields JA. Headache or eye pain as the presenting feature of uveal melanoma. Ophthalmology. 2013;120(9):1946-1947, 1946.e1-1947.e2. doi:10.10‌16/‌j.ophtha.2013.06.015
  15. Francis JH, Shoushtari AN, Barker CA, Abramson DH. Uveal melanoma: diagnosis, prognosis and current treatments for primary and metastatic disease. Melanoma Lett. 2016;34(3). Accessed December 13, 2018. ht‌tps://ww‌w.skincancer.or‌g​/publications​/the-mela‌noma-letter​/fall-201‌6-vol-34-no-3​/uveal-melanoma
  16. Kivelä T, Simpson ER, Grossniklaus HE, et al. Uveal melanoma. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:805-817.
  17. Damato B, Eleuteri A, Taktak AFG, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 2011;30(5):285-295. doi:10.1016/j.preteyeres.2011.05.003
  18. DeParis SW, Taktak A, Eleuteri A, et al. External validation of the Liverpool Uveal Melanoma Prognosticator Online. Invest Ophthalmol Vis Sci. 2016;57(14):6‌116-6‌122. doi:10.1167/iovs.16-19654
  19. Kivelä T. Diagnosis of uveal melanoma. In: Jager MJ, Desjardins L, Kivelä T, Damato BE, eds. Current Concepts in Uveal Melanoma. Karger; 2012. Bandello F, ed. Developments in Ophthalmology; vol 49.
  20. Collaborative Ocular Melanoma Study (COMS) Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, V: twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124:1684-1693, E1-E3. doi:10.1001‌/arc‌hopht.12‌4.12.1684
  21. Singh M, Durairaj P, Yeung J. Uveal melanoma: a review of the literature. Oncol Ther. 2018;6(1):87-104. doi:10.1007‌/s404‌87-0‌18-00‌56-8
  22. Bensoussan E, Thariat J, Maschi C, et al. Outcomes after proton beam therapy for large choroidal melanomas in 492 patients. Am J Ophthalmol. 2016;165:78-87. doi:10.1016/j.‌ajo.201‌6.02.027
  23. Carvajal RD. Management of metastatic uveal melanoma. UpToDate. Updated September 30, 2019. Accessed April 14, 2020. htt‌ps://w‌ww.uptodate.co‌m​/contents​/management-of-metas‌tatic-uveal-melanoma
  24. Vaquero-Garcia J, Lalonde E, Ewens KG, et al. PRiMeUM: a model for predicting risk of metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2017;58(10):40‌96-41‌05. doi:10.‌1167/iovs.1‌7-2‌2255
  25. Corrêa ZM. Assessing prognosis in uveal melanoma. Cancer Control. 2016;23(2):93-98. doi:10.1177/10‌7327‌48‌16‌0230‌0202
  26. Francis JH, Patel SP, Gombos DS, Carvajal RD. Surveillance options for patients with uveal melanoma following definitive management. In: Dizon DS, ed. American Society of Clinical Oncology Educational Book. Vol 33. American Society of Clinical Oncology; 2013:382-387. doi:10.14694/EdBook_AM.2013.33.382
The information and other content contained on this website are not intended to be, nor should they be, used as medical advice, diagnosis, or treatment. Each patient must be evaluated, diagnosed, and treated based upon that individual patient’s specific circumstances.